RB1 and ovarian cancer: Consistent with this mechanism, previous reports have shown that CDKN2A-low/RB1-proficient ovarian cancer cells were most responsive to CDK4/6 inhibition [14] and that RB1 loss was a mechanism of resistance to CDK4/6 inhibition.